FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2945387816> ?p ?o ?g. }

• W2945387816 endingPage "1594" @default.
• W2945387816 startingPage "1593" @default.
• W2945387816 abstract "QTc dispersion (QTcd) tended to be decreased at 24 weeks and was significantly decreased at 2 years after dapagliflozin treatment. In the subgroup with QTcd?53.7 ms (median), QTcd was significantly decreased at 24 weeks and remained improved for 2 years. Dapagliflozin also significantly reduced Tpeak-Tend/QT in a subgroup with Tpeak-Tend/QT?0.25 (median). Increased ventricular repolarization heterogeneity (VRH) is one of the predictors of poor cardiovascular prognosis in patients with type 2 diabetes. Our retrospective studies1, 2 have shown that increased VRH in patients with type 2 diabetes is reversed by treatment with a sodium–glucose cotransporter 2 (SGLT2) inhibitor, but not by other oral hypoglycemic agents, and the result of a recent retrospective study3 also suggested that an SGLT2 inhibitor has a beneficial effect on VRH in type 2 diabetes. However, to our knowledge, no study in the literature has prospectively examined the effect of an SGLT2 inhibitor on type 2 diabetes-induced VRH. Thus, we prospectively assessed QTc dispersion (QTcd) and Tpeak-Tend/QT in lead V5, electrocardiographic indices of VRH, in 25 patients with type 2 diabetes who had been treated with dapagliflozin 5 mg once daily for 2 years. This study was approved by the institutional review board of Ehime University Graduate School of Medicine. Inclusion and exclusion criteria were as described previously2, 4. Baseline patient characteristics were as follows: 60% participants were men, age was 57.8 ± 12.2 years, median duration of diabetes was 13.0 years (interquartile range [IQR] 7.3–20.5 years), body mass index was 30.0 ± 9.2 kg/m2, glycated hemoglobin was 7.6 ± 1.1% and blood pressure was 139 ± 18/80 ±14 mmHg. At 24 weeks after the treatment, body mass index, glycated hemoglobin and blood pressure were decreased to 27.4 ± 4.1 kg/m2, 7.2 ± 0.8% and 127 ± 13/70 ± 11 mmHg, respectively, and the trends were maintained thereafter. QTc dispersion tended to be decreased at 24 weeks, and was significantly decreased at 2 years after dapagliflozin treatment compared with that at baseline (Figure 1). As the protective effect of SGLT2 inhibitors was greater in patients with larger VRH at baseline2, 3, the patients were divided into two subgroups by the median of QTcd (53.7 ms). In the subgroup with QTcd ≥53.7 ms, QTcd was significantly decreased at 24 weeks (from 68.3 ms [IQR 57.0–83.6 ms] at baseline to 56.5 ms [IQR 45.3–61.6 ms], P = 0.022), and remained improved for 2 years (46.1 ms [IQR 39.9–58.3 ms], P = 0.002). In contrast, in the subgroup with QTcd <53.7 ms, QTcd (48.6 ms [IQR 42.4–51.7 ms] at baseline) was unaffected by treatment. As for Tpeak-Tend/QT, improvement by dapagliflozin was not significant when all participants were included in the analysis. However, in a subgroup with Tpeak-Tend/QT ≥0.25 (median), dapagliflozin significantly reduced Tpeak-Tend/QT at 24 weeks (from 0.267 [IQR 0.254–0.323] at baseline to 0.262 [IQR 0.243–0.274], P = 0.008) and at 2 years (0.255 [IQR 0.243–0.265], P =0.013). Changes in QTcd and Tpeak-Tend/QT were not correlated with change in glycated hemoglobin after dapagliflozin treatment, even in the larger VRH subgroups. Heart rate and QTc interval were not altered by dapagliflozin treatment. Together with retrospective studies2, 3, the present prospective study supports the notion that treatment with an SGLT2 inhibitor improves VRH in patients with type 2 diabetes for years. Intriguingly, the improvement of VRH after SGLT2 inhibitor treatment was independent of glycemic control, as was found in a previous study2, and thus it might be attributable to pleiotropic effects of this class of agents. Nevertheless, as VRH is a risk factor of lethal cardiac events, reversal of diabetes-induced VRH is one of the possible mechanisms by which SGLT2 inhibitors reduce cardiac mortality, particularly sudden cardiac death, in patients with type 2 diabetes. This study was supported by a grant from Ono Pharmaceutical Co., Ltd. and AstraZeneca. The authors thank Mr Yasuyuki Takeda for his financial support, which was provided without any conflict of interest. TS, TaM, SF, MT and TeM received lecture honoraria for lectures from Ono Pharmaceutical Co., Ltd. and AstraZeneca. The other authors declare no conflict of interest." @default.
• W2945387816 created "2019-05-29" @default.
• W2945387816 creator A5015624012 @default.
• W2945387816 creator A5035134420 @default.
• W2945387816 creator A5039100229 @default.
• W2945387816 creator A5044149153 @default.
• W2945387816 creator A5066341447 @default.
• W2945387816 creator A5067308604 @default.
• W2945387816 creator A5070864329 @default.
• W2945387816 creator A5087484635 @default.
• W2945387816 date "2019-05-15" @default.
• W2945387816 modified "2023-10-17" @default.
• W2945387816 title "Longitudinal impact of dapagliflozin treatment on ventricular repolarization heterogeneity in patients with type 2 diabetes" @default.
• W2945387816 cites W2100650211 @default.
• W2945387816 cites W2735739571 @default.
• W2945387816 cites W2883444112 @default.
• W2945387816 cites W2905151803 @default.
• W2945387816 doi "https://doi.org/10.1111/jdi.13063" @default.
• W2945387816 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6825944" @default.
• W2945387816 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31090258" @default.
• W2945387816 hasPublicationYear "2019" @default.
• W2945387816 type Work @default.
• W2945387816 sameAs 2945387816 @default.
• W2945387816 citedByCount "4" @default.
• W2945387816 countsByYear W29453878162020 @default.
• W2945387816 countsByYear W29453878162021 @default.
• W2945387816 countsByYear W29453878162022 @default.
• W2945387816 countsByYear W29453878162023 @default.
• W2945387816 crossrefType "journal-article" @default.
• W2945387816 hasAuthorship W2945387816A5015624012 @default.
• W2945387816 hasAuthorship W2945387816A5035134420 @default.
• W2945387816 hasAuthorship W2945387816A5039100229 @default.
• W2945387816 hasAuthorship W2945387816A5044149153 @default.
• W2945387816 hasAuthorship W2945387816A5066341447 @default.
• W2945387816 hasAuthorship W2945387816A5067308604 @default.
• W2945387816 hasAuthorship W2945387816A5070864329 @default.
• W2945387816 hasAuthorship W2945387816A5087484635 @default.
• W2945387816 hasBestOaLocation W29453878161 @default.
• W2945387816 hasConcept C118441451 @default.
• W2945387816 hasConcept C119060515 @default.
• W2945387816 hasConcept C126322002 @default.
• W2945387816 hasConcept C134018914 @default.
• W2945387816 hasConcept C164705383 @default.
• W2945387816 hasConcept C167135981 @default.
• W2945387816 hasConcept C2777180221 @default.
• W2945387816 hasConcept C2777422806 @default.
• W2945387816 hasConcept C555293320 @default.
• W2945387816 hasConcept C71924100 @default.
• W2945387816 hasConceptScore W2945387816C118441451 @default.
• W2945387816 hasConceptScore W2945387816C119060515 @default.
• W2945387816 hasConceptScore W2945387816C126322002 @default.
• W2945387816 hasConceptScore W2945387816C134018914 @default.
• W2945387816 hasConceptScore W2945387816C164705383 @default.
• W2945387816 hasConceptScore W2945387816C167135981 @default.
• W2945387816 hasConceptScore W2945387816C2777180221 @default.
• W2945387816 hasConceptScore W2945387816C2777422806 @default.
• W2945387816 hasConceptScore W2945387816C555293320 @default.
• W2945387816 hasConceptScore W2945387816C71924100 @default.
• W2945387816 hasFunder F4320307770 @default.
• W2945387816 hasIssue "6" @default.
• W2945387816 hasLocation W29453878161 @default.
• W2945387816 hasLocation W29453878162 @default.
• W2945387816 hasLocation W29453878163 @default.
• W2945387816 hasOpenAccess W2945387816 @default.
• W2945387816 hasPrimaryLocation W29453878161 @default.
• W2945387816 hasRelatedWork W1563850031 @default.
• W2945387816 hasRelatedWork W2061253854 @default.
• W2945387816 hasRelatedWork W2095627701 @default.
• W2945387816 hasRelatedWork W2237317573 @default.
• W2945387816 hasRelatedWork W2415759662 @default.
• W2945387816 hasRelatedWork W2601895312 @default.
• W2945387816 hasRelatedWork W2971392718 @default.
• W2945387816 hasRelatedWork W3036934084 @default.
• W2945387816 hasRelatedWork W3162511055 @default.
• W2945387816 hasRelatedWork W4308834491 @default.
• W2945387816 hasVolume "10" @default.
• W2945387816 isParatext "false" @default.
• W2945387816 isRetracted "false" @default.
• W2945387816 magId "2945387816" @default.
• W2945387816 workType "article" @default.